4:44 PM
 | 
Jan 10, 2019
 |  BC Extra  |  Preclinical News

UW team builds protein that avoids IL-2 toxicities, forms Neoleukin to develop

University of Washington researchers published a Nature paper Wednesday detailing the construction of a synthetic protein that selectively binds to IL-2 to avoid toxicities that have previously overshadowed interest in the receptor as a therapeutic target. Several of the study authors have formed Neoleukin Therapeutics Inc. (Seattle, Wash.) to develop the synthetic protein, dubbed NEO-201.

Because the IL-2 receptor has two variants expressed on different cell types, targeting the receptor can lead to severe toxicities, including life-threatening pulmonary edema, hypotension and capillary leak syndrome. Binding to the intermediate-affinity form -- comprising...

Read the full 442 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >